Abstract
We report a rare case of PDL1-negative advanced gastric adenocarcinoma that improved significantly after camrelizumab plus chemotherapy followed by camrelizumab plus capecitabine as first-line therapy. A 65-year-old woman was diagnosed with a gastric adenocarcinoma in 2017 via contrast-enhanced computed tomography (CT) and endoscopic biopsy. She stabilised after preoperative neoadjuvant chemotherapy, surgery, and postoperative adjuvant chemotherapy. In September 2019, positron emission tomography (PET)/CT re-examination suggested a peritoneal metastasis and multiple lymph node metastases. She then received six cycles of camrelizumab plus chemotherapy. PET/CT indicated that the metastatic foci had disappeared and that she had achieved a clinical complete response(CCR). She was followed-up with camrelizumab plus capecitabine (maintenance therapy). At the time of writing, her progression-free survival is more than 14 months and her quality of life is good. Thus, camrelizumab plus chemotherapy is a useful first-line treatment for HER2- and PD-L1-negative advanced gastric adenocarcinoma.
Highlights
Gastric cancer is the fifth most common cancer worldwide and the fourth leading cause of cancerrelated death [1]
Increasing evidence suggests that immunotherapy and chemotherapy exert synergistic anti-tumour effects
The CheckMate 649 trial confirmed that nivolumab plus chemotherapy afforded significant clinical benefits in terms of overall survival (OS) and PFS in patients with PD-L1 combined positive scores of five or more, or one or more [5]
Summary
Gastric cancer is the fifth most common cancer worldwide and the fourth leading cause of cancerrelated death [1]. The patient achieved a clinical complete response (CCR) after six cycles of treatment with carrizumab plus capecitabine, and her progression-free survival (PFS) is currently 14 months on maintenance treatment with carrizumab plus capecitabine Such treatment may be useful for patients with advanced gastric adenocarcinomas. After camrelizumab plus CAPOX (capecitabine plus oxaliplatin; six courses), PET/CT reexamination on May 6th, 2020, indicated the disappearance of all lesions in the right lower chest wall and the abdominal peritoneum Based on the remarkable efficacy of camrelizumab plus CAPOX, we continued camrelizumab plus capecitabine maintenance therapy To date, her quality of life is good, no new tumors have been detected on regular contrast-enhanced CT (Figure 2), and the symptom of right lower abdominal pain has disappeared completely(the NRS score was reduced from 8 to 0).
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
